VDR and Alzheimer disease: Bisdemethoxycurcumin (BDC) pretreatment in an ex vivo study on peripheral blood mononuclear cells (PBMCs) of AD patients showed that curcumin decreases mRNA levels of NFκB, BACE1 and Toll-like receptor and upregulates mRNA levels of mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (MGAT3) and vitamin D receptor (VDR), leading to diminished Aβ aggregates [51].